HR001, a Novel CD19-targeted CAR-T Cell Therapy for Patients with Relapsed/refractory Non-Hodgkin's Lymphoma: Primary Results of a Phase II Study (HRAIN01-NHL01-II)
CANCER RESEARCH（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined